Genetic variability of CYP2D6, CYP2B6, CYP2C9 and CYP2C19 genes across the Italian Peninsula

被引:10
|
作者
Carano, Francesco [1 ]
Sarno, Stefania [2 ]
De Fanti, Sara [2 ]
Serventi, Patrizia [2 ,3 ]
Bini, Carla [1 ]
Luiselli, Donata [2 ]
Pelotti, Susi [1 ]
机构
[1] Univ Bologna, Inst Legal Med, Dept Med & Surg Sci, Bologna, Italy
[2] Univ Bologna, Dept Biol Geol & Environm Sci, Mol Anthropol Lab, Bologna, Italy
[3] Alma Mater Studiorum Univ Bologna, Dept Cultural Heritage, Ravenna, Italy
基金
欧洲研究理事会;
关键词
Pharmacogenetics; cytochrome-P450 (CYP) genes; Italian population; genetic variation; geographic structure; GENOTYPE; POLYMORPHISMS; VARIANTS; EXPRESSION; JAPANESE; ENZYMES; ALLELE; PCR;
D O I
10.1080/03014460.2017.1378368
中图分类号
Q98 [人类学];
学科分类号
030303 ;
摘要
Background: Environmental conditions and past migratory events may have shaped genetic heterogeneity of clinically relevant enzymes involved in the phase I metabolism of the most common therapeutic drugs.Aim: To investigate the genetic variability of CYP2D6, CYP2B6, CYP2C19 and CYP2C9 across the Italian Peninsula, by sampling only ancestrally and geographically homogeneous individuals from northern, central and southern Italy.Subjects and methods: A total of 25 SNPs were genotyped in 174 unrelated Italian individuals by means of multiplex PCR and minisequencing reactions. CYP2D6 genotypic data were used to predict phenotypes and the phylogenetic relationships among reconstructed haplotypes were represented by means of a Median Joining Network.Results: Pairwise Fisher Exact tests revealed significant differences between northern and southern Italy in the distribution of CYP2C19 genotypes, with the CYP2C19*2 allele appearing over-represented in northern Italy. Likewise, significant differences in the distribution of CYP2D6 genotypes (*4/*3, *4/*4 and *6/*4) responsible for the poor metabolizer phenotype were observed in northern with respect to both central and southern Italy.Conclusions: The north-south structuring pattern showed by CYP2D6 and CYP2C19 underline how a deeper knowledge of the geographic distribution of alleles may improve clinical practice and help to avoid hypothetical bias in drug trials.
引用
收藏
页码:66 / 71
页数:6
相关论文
共 50 条
  • [21] Genetic polymorphisms of cytochromes P450: CYP2C9, CYP2C19, and CYP2D6 in Croatian population
    Bozina, N
    Granic, P
    Lalic, Z
    Tramisak, I
    Lovric, M
    Stavljenic-Rukavina, A
    CROATIAN MEDICAL JOURNAL, 2003, 44 (04) : 425 - 428
  • [22] Genetic and phenotypic frequency distribution of CYP2C9, CYP2C19 and CYP2D6 in over 3200 Han Chinese
    He, Li
    Chen, Shaojun
    Li, Jingao
    Xie, Xiaoxue
    Huang, Lihua
    Kuang, Yun
    Xu, Kangwei
    Huang, Wanxia
    Zhao, Yanling
    Yang, Guoping
    Guo, Chengxian
    CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY, 2020, 47 (10) : 1659 - 1663
  • [23] Relevance of CYP2C9, CYP2C19, CYP2B6 and GSTA1 polymorphisms on cyclophosphamide kinetics
    Timm, R
    Kaiser, R
    Sezer, O
    Weisz, K
    Roots, I
    Cascorbi, I
    NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY, 2004, 369 : R149 - R149
  • [24] Methadone enantiomer plasma levels, CYP2B6, CYP2C19, and CYP2C9 genotypes, and response to treatment
    Crettol, S
    Déglon, JJ
    Besson, J
    Croquette-Krokkar, M
    Gothuey, I
    Hämmig, R
    Monnat, M
    Hüttemann, H
    Baumann, P
    Eap, CB
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2005, 78 (06) : 593 - 604
  • [25] Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
    Wang, Jing
    Zhang, Zhi-Yi
    Lu, Sharon
    Powers, Dan
    Kansra, Vikram
    Wang, Xiaodong
    SUPPORTIVE CARE IN CANCER, 2019, 27 (03) : 819 - 827
  • [26] Effects of rolapitant administered orally on the pharmacokinetics of dextromethorphan (CYP2D6), tolbutamide (CYP2C9), omeprazole (CYP2C19), efavirenz (CYP2B6), and repaglinide (CYP2C8) in healthy subjects
    Jing Wang
    Zhi-Yi Zhang
    Sharon Lu
    Dan Powers
    Vikram Kansra
    Xiaodong Wang
    Supportive Care in Cancer, 2019, 27 : 819 - 827
  • [27] VARIABILITY IN SERTRALINE PHARMACOKINETICS EXPLAINED BY CYP2C19 AND CYP2B6
    Ramsey, Laura B.
    Poweleit, Ethan A.
    Vaughn, Samuel
    Momper, Jeremiah
    Desta, Zeruesenay
    Strawn, Jeffrey Robert
    JOURNAL OF THE AMERICAN ACADEMY OF CHILD AND ADOLESCENT PSYCHIATRY, 2024, 63 (10): : S194 - S194
  • [28] Association of Pharmacogenomic Phenotypes in CYP2D6, CYP2C9, CYP2C19, and CYP3A5 on Polypharmacy in Veterans
    Krulikas, Linas
    Bates, Jill
    Chanfreau, Catherine
    Coleman, Heather
    Dalton, Shawn
    Voora, Deepak
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (02) : 390 - 396
  • [29] Determination of CYP2D6, CYP2C9 and CYP2C19 genotypes with Tag-It™ mutation detection assays
    Melis, Roberto
    Lyon, Elaine
    McMillin, Gwendolyn A.
    EXPERT REVIEW OF MOLECULAR DIAGNOSTICS, 2006, 6 (06) : 811 - 820
  • [30] Genetic polimorphism of CYP2C9 and CYP2D6 in the Croatian population
    Bozina, N
    Tramisak, I
    Granic, P
    Stavljenic-Rukavina, A
    EUROPEAN JOURNAL OF HUMAN GENETICS, 2002, 10 : 187 - 187